Abstract
The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Current Medicinal Chemistry
Title:Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Volume: 19 Issue: 21
Author(s): D. P. Zlotos
Affiliation:
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Abstract: The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Export Options
About this article
Cite this article as:
P. Zlotos D., Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323153
DOI https://dx.doi.org/10.2174/092986712801323153 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram
Current Radiopharmaceuticals The Diterpenoids of the Genus Elaeoselinum (Apiaceae) and their Biological Properties
Current Organic Chemistry Therapeutic Potentials of Recently Identified PLD Inhibitors
Current Chemical Biology Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients' Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity
Current Pharmaceutical Design Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Letters in Drug Design & Discovery The Structure and Pharmacological Functions of Coumarins and Their Derivatives
Current Medicinal Chemistry